Evidence map›Paper›PMID 31939811›Full record

ArticleCritical care medicine2020

Formyl Peptide Receptor-1 Blockade Prevents Receptor Regulation by Mitochondrial Danger-Associated Molecular Patterns and Preserves Neutrophil Function After Trauma.

Kiyoshi Itagaki, Elzbieta Kaczmarek, Woon Yong Kwon, Li Chen, Barbora Vlková, Quanzhi Zhang, Ingred Riça, Michael B Yaffe, Yan Campbell, Michael F Marusich and 7 more

Open access · greenAbstract read
In one paragraph

Article in Critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Can Neutrophils Prevent Nosocomial Pneumonia after Serious Injury?International journal of molecular sciences · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Circulating mitochondrialProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 4 countries.

Kiyoshi ItagakiDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Elzbieta KaczmarekDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Woon Yong KwonDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Li ChenDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Barbora VlkováDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Quanzhi ZhangDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Ingred RiçaThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
Michael B YaffeThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA.
Yan CampbellmAbDx, Eugene, OR.
Michael F MarusichmAbDx, Eugene, OR.
Ji Ming WangNational Cancer Institute/National Institutes of Health, Frederick, MD.
Wang-Hua GongNational Cancer Institute/National Institutes of Health, Frederick, MD.
Ji-Liang GaoNational Institute of Allergy and Infectious Diseases/National Institutes of Health, Frederick, MD.
Françoise JungPolyphor LTD, Allschwil, Switzerland.
Garry DouglasPolyphor LTD, Allschwil, Switzerland.
Leo E OtterbeinDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Carl J HauserDepartment of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Beth Israel Deaconess Medical Center · USHarvard University · USMassachusetts Institute of Technology · US

Funding

Molecular Analysis Of Leukocyte Activation By ChemoattractantsZIAAI000615 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MURPHY, PHILIP · 2009 to 2025
$44.8M
The Role of Cellular Receptors Involved in Inflammation and Tumor ProgressionZIABC010015 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, JI MING · 2009 to 2023
$6.3M
Role of Formylpeptide Receptors in Host DefenseZIABC010725 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, JI MING · 2009 to 2023
$6.3M
mtDAMPs and nosocomial pneumonia after injuryR03AI135346 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ITAGAKI, KIYOSHI · 2018 to 2019
$175k
NIAID NIH HHS R03 AI135346
6 · The paper itself

Abstract

objectivesTrauma predisposes to systemic sterile inflammation (systemic inflammatory response syndrome) as well as infection, but the mechanisms linking injury to infection are poorly understood. Mitochondrial debris contains formyl peptides. These bind formyl peptide receptor-1, trafficking neutrophils to wounds, initiating systemic inflammatory response syndrome, and wound healing. Bacterial formyl peptides, however, also attract neutrophils via formyl peptide receptor-1. Thus, mitochondrial formyl peptides might suppress neutrophils antimicrobial function. Also, formyl peptide receptor-1 blockade used to mitigate systemic inflammatory response syndrome might predispose to sepsis. We examined how mitochondrial formyl peptides impact neutrophils functions contributing to antimicrobial responses and how formyl peptide receptor-1 antagonists affect those functions.

designProspective study of human and murine neutrophils and clinical cohort analysis.

settingUniversity research laboratory and level 1 trauma center. PATIENTS: Trauma patients, volunteer controls. ANIMAL SUBJECTS: C57Bl/6, formyl peptide receptor-1, and formyl peptide receptor-2 knockout mice.

interventionsHuman and murine neutrophils functions were activated with autologous mitochondrial debris, mitochondrial formyl peptides, or bacterial formyl peptides followed by chemokines or leukotrienes. The experiments were repeated using formyl peptide receptor-1 antagonist cyclosporin H, "designer" human formyl peptide receptor-1 antagonists (POL7178 and POL7200), or anti-formyl peptide receptor-1 antibodies. Mouse injury/lung infection model was used to evaluate effect of formyl peptide receptor-1 inhibition. MEASUREMENTS AND MAIN

resultsHuman neutrophils cytosolic calcium, chemotaxis, reactive oxygen species production, and phagocytosis were studied before and after exposure to mitochondrial debris, mitochondrial formyl peptides, and bacterial formyl peptides. Mitochondrial formyl peptide and bacterial formyl peptides had similar effects on neutrophils. Responses to chemokines and leukotrienes were suppressed by prior exposure to formyl peptides. POL7200 and POL7178 were specific antagonists of human formyl peptide receptor-1 and more effective than cyclosporin H or anti-formyl peptide receptor-1 antibodies. Formyl peptides inhibited mouse neutrophils responses to chemokines only if formyl peptide receptor-1 was present. Formyl peptide receptor-1 blockade did not inhibit neutrophils bacterial phagocytosis or reactive oxygen species production. Cyclosporin H increased bacterial clearance in lungs after injury.

conclusionsFormyl peptides both activate and desensitize neutrophils. Formyl peptide receptor-1 blockade prevents desensitization, potentially both diminishing systemic inflammatory response syndrome and protecting the host against secondary infection after tissue trauma or primary infection.

Indexed as

AnimalsCyclosporineHumansLung InjuryMiceMice, Inbred C57BLMitochondrial ProteinsNeutrophil ActivationNeutrophilsReceptors, Formyl PeptideRespiratory Tract InfectionsCyclosporinecyclosporin HFPR1 protein, humanMitochondrial ProteinsReceptors, Formyl Peptide

Identifiers

PMID31939811
PMCPMC7337247
OpenAlexW2988042292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.